Clinical trials in Bologna – page 9

885 clinical trials in Bologna, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Bologna at a glance

885

clinical trials

Research sites4

Quick filters

885 trials in Bologna

Open in trial search

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

Italy

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Letrozole
Sponsor:Olema Pharmaceuticals Inc.

Contact Research Centre

Neoplasm malignant

Recruiting

A study of DS-3790A, rituximab, and epcoritamab in patients with blood cancers

Registered drugNo placebo

A study of DS-3790A, rituximab, and epcoritamab in patients with blood cancers

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Mantle cell lymphoma

Recruiting

A study to evaluate the effectiveness of pirtobrutinib in elderly and frail patients with mantle cell lymphoma who have not yet received treatment.

Registered drugNo placebo

A study to evaluate the effectiveness of pirtobrutinib in elderly and frail patients with mantle cell lymphoma who have not yet received treatment.

Registered drugNo placebo

Italy

Participants:65+ years
Substances:Pirtobrutinib
Sponsor:Fondazione Italiana Linfomi Ets

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Revumenib, Cytarabine, and Fludarabine in Children with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo

Study of Revumenib, Cytarabine, and Fludarabine in Children with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Cytarabine
Sponsor:Pediatric Research International GmbH

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Kura Oncology Inc.

Contact Research Centre

Autoimmune haemolytic anaemia+1

Recruiting

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Tafasitamab
Sponsor:Incyte Corp.

Contact Research Centre

Acute leukaemia

Recruiting

A study of Enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo

A study of Enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Sumitomo Pharma America Inc.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Ly3437943 Sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Gastrointestinal cancer metastatic

Recruiting

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Sunitinib
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Cardiac failure+1

Recruiting

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Finerenone
Sponsor:Bayer AG

Contact Research Centre

Cardiac failure+1

Recruiting

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational

Italy

Participants:0–17 years
Substances:Finerenone
Sponsor:Bayer AG

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 233 cities in Italy

Clinical research in Bologna

What the registry says about research in the country

01 Hematological Disorders

Innovative research focusing on Immune Thrombocytopenia and various forms of blood cancers including Acute Myeloid Leukemia and Multiple Myeloma. These trials aim to evaluate novel therapeutic approaches and combination treatments.

Blood Disorders
Leukemia Research
Immunology Studies

Studies include evaluation of new compounds and their safety profiles in treating various blood-related conditions.

02 Gastrointestinal Research

Comprehensive studies on inflammatory bowel conditions, focusing on Crohn's Disease and Ulcerative Colitis. Research aims to develop more effective treatments for patients with moderate to severe disease activity.

Inflammatory Bowel Disease
Treatment Response
Disease Management

Trials evaluate both induction therapy and long-term treatment options for gastrointestinal conditions.

03 Neurological Conditions

Investigation of treatments for sleep disorders including Narcolepsy and Idiopathic Hypersomnia, along with research into Chronic Inflammatory Demyelinating Polyneuropathy.

Sleep Disorders
Neurological Diseases
Treatment Safety

Focus on developing safer and more effective therapies for various neurological conditions.

Back to Italy All countries